SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck Ends Development of Blood Cancer Drug Nemtabrutinib

Merck is ending clinical development of nemtabrutinib, which was being evaluated for chronic lymphocytic leukemia, small lymphocytic leukemia and other blood cancers.

MRK

Related stories